Eluminex Biosciences Announces Completion of Initial Enrollment in Part A of the CLARITY Study Evaluating a Human Recombinant Collagen-derived (rhCIII) Biosynthetic Cornea (EB-301)
- Written by PR Newswire
Initial Part A results to be presented at the upcoming American Society of Cataract and Refractive Surgery Annual Meeting
EB-301 has the potential to be the world's first approved rhCIII biosynthetic corneal implant for the treatment of corneal blindness
SUZHOU, China and SAN FRANCISCO, Feb. 15, 2023 /PRNewswire/ -- Eluminex Biosciences today...